http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9623031-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_709b4a26ef028713f9b302509eb824d7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-202 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-202 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 |
| filingDate | 2016-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a0c4ae4c1503d6af6a54b1ba824b89d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5e1300933b6a2e7e93bfd1891ff0218 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a2a6d0df4556a386b25816452f7fba6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ce2e0e6cdd44552bccc5ddc64b030d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a63b8f1fb026f59b42b04e4fa33c2f7b |
| publicationDate | 2017-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9623031-B2 |
| titleOfInvention | Compositions, methods and kits for treating cancer |
| abstract | Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: Δ 12 -prostaglandin J 3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. Δ 12 -prostaglandin J 3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. Δ 12 -prostaglandin J 3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs. |
| priorityDate | 2011-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 103.